0HB0 trade ideas
AGIO w24 2021. Waiting for clear uptrend.Weekly
Company not so old.
Consolidation of price
Daily
If price holds level of 57 could be buy, but i suppose profit depends on how fast they will do resarch of anticancer in 2022-2024 years.
Long on AGIOIsland type Reversal pattern on Abnormal Volume
New 30bar Highs on 2period ROC
Climactic action and supple demand imbalance
Longer term Wolf wave pattern on Weeklys and Daily’s
$AGIO Agios shares jump- sells Cancer Portfolio for $1.8bil
Could be a runner today on the news that is has agreed to sell its cancer portfolio .
"Servier will pay $1.8 billion in cash upfront and $200 million in potential future milestone payments for vorasidenib as well as a small percentage of royalties for U.S. net sales of acute myeloid leukemia treatment Tibsovo and U.S. net sales of vorasidenib, if the experimental therapy is approved by the Food and Drug Administration. " source marketwatch
Its is worth noting that the company currently has a M/C of $2.3 billion .
Todays action very much depends on activity among day traders.
The stock also carries a 8% short interest whom may fell a squeeze.
I have included levels to watch and in particular the 200ma and gap fill resistance.
Agios Pharmaceuticals, Inc. Spikes pre market Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.
Shares of Agios Pharmaceuticals Inc. AGIO, -0.63% soared 20.6% in premarket trading on Monday after the company said it is selling its oncology portfolio to Servier, a privately held French pharmaceutical company. Servier will pay $1.8 billion in cash upfront and $200 million in potential future milestone payments for vorasidenib as well as a small percentage of royalties for U.S. net sales of acute myeloid leukemia treatment Tibsovo and U.S. net sales of vorasidenib, if the experimental therapy is approved by the Food and Drug Administration. The deal is expected to close in the second quarter of next year. Shares of Agios have tumbled 30.0% this year, while the S&P 500 SPX, -0.35% is up 14.8%.
$AGIO Agios Pharma Bullish Trade above the 200MA
Alert set for break above the 200MA.
A cross above mid channel would be very bullish setting up a
move to the top of channel.
RSi very strong bounce of Mid-point
Volume beginning to increase
Short term target $46- $48
Agios Announces FDA Orphan Drug Designation Granted to MitapivatAGIO: Agios Pharmaceuticals, Inc.
2020-11-12 16:30:16
Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Sickle Cell Disease
AGIO 8H: BEST Level to BUY/HOLD 90% gains(SL/TP)(STOCKS)Why get subbed to me on Tradingview?
-TOP author on TradingView
-15+ years experience in markets
-Professional chart break downs
-Supply/Demand Zones
-TD9 counts / combo review
-Key S/R levels
-No junk on my charts
-Frequent updates
-Covering FX/crypto/US stocks
-24/7 uptime so constant updates
AGIO 8H: BEST Level to BUY/HOLD 90% gains(SL/TP)(STOCKS)
IMPORTANT NOTE: speculative setup. do your own
due dill. use STOP LOSS. don't overleverage.
🔸 Summary and potential trade setup
::: AGIO 8hour chart review and outlook
::: Biotech sector outperforming market
::: Currenly in accumulation stage
::: Buying low near range lows
::: is the best strategy BULLS
::: wait for pullback/dips and BUY IT
::: recommended strategy: BUY LOW 25/26 USD
::: SL 20 US TP is 58/60 USD +90%/+100% gains
::: BUY/HOLD setup
::: DO NOT expect overnight gains
::: This is stock market
:::Not casino in Macau
🔸 Supply/Demand Zones
. N/A
🔸 Why should I follow your setups?
:::Check track record it's all been posted
::: MRNA 200%+ gains, NVAX 300% gains, REG 60%
::: AMD 40% gains and a lot more in 2020
Agios Announces FDA Orphan Drug Designation Granted to MitapivatAGIO: Agios Pharmaceuticals, Inc.
2020-06-08 16:01:10
Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Thalassemia
AGIO D1 XABCD 80% gains(STOCKS)before we kick start the update. your upvotes/subs are appreciated.
Why get subbed to to me on Tradingview?
-15+ years real live trading experience
-TOP Author on TradingView
-professional chart break downs
-key levels
-no junk on my charts
-frequent updates
-covering FX/crypto/US stocks
-24/7 uptime so constant updates
So without further due. Keep it short/simple and to the point.
AGIO D1 XABCD 80% gains(STOCKS)
IMPORTANT NOTE: this is speculative setup.
results not guaranteed. do your own due dill.
at all times please use a stop loss.
AGIO daily. speculative XABCD setup.
load point bulls 32 USD. use tight SL.
80% upside in this setup.
BUY/HOLD setup. do not expect miracle
overnight gains. hold time 40-90 days.
SPECULATIVE SETUP. USE TIGHT SL.
good luck traders!
get subbed to stay tuned for all the latest updates.
also add likes to support my efforts, thank you.
$AGIO Bullish after-hours 15% move on positive 8-K filing.Shares have made a very positive move afterhours on good volume after the release of its 8-K Inc announcing that the global phase 3 ClarIDHy trial of TIBSOVO® (ivosidenib) in previously treated cholangiocarcinoma patients with an isocitrate dehydrogenase 1 mutation met its primary endpoint. Tomorrow will be a very positive day so be ready, it could move very fast.
Analyst average Recommendation Overweight
9 BUY
3 HOLD
Analyst average price target $85
Company Description
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.
AGIOS SHORTThe bullis trend has been turned with Head and Shoulders formation. The resistance trend line do not allow the price to grow, up to now touched that line 4. times. If it will not penetrate fifth time, that is a big chance to move down to 50$
Agios Pharmacuticals (AIGO) PERFECT SHORT OPPURTUNITY 8-15-18 This is a perfect opportunity to short this stock. Every singe Ichimoku indicator signifies that this is a perfect opportunity. It also signifies it will continue to drop for quite a while.
The indicators used are:
1) Gann Fan
2) Kumo Cloud
3) Tenkan-Sen and Kijun-Sen
4) Chikou line is now free
5) Price-Volume Trendline
6) Stoch Index
Disclaimer: I am just sharing my opinion
Bullish on Agios-Company waiting Priority Review for Enasidenib in Relapsed or Refractory AML with an IDH2 Mutation from the FDA (Due early August).
-Thier IDH1m (IVOSIDENIB) looks somewhat promising
- They are currently at 53.84 which is low given the above two points. NASDAQ:AGIO
